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Detection of DNA methylation in the genome has been possible for decades; however, the ability to deliberately and spe-
cifically manipulate local DNAmethylation states in the genome has been extremely limited. Consequently, this has imped-
ed our understanding of the direct effect of DNA methylation on transcriptional regulation and transcription factor
binding in the native chromatin context. Thus, highly specific targeted epigenome editing tools are needed to address
this. Recent adaptations of genome editing technologies, including fusion of the DNMT3A DNA methyltransferase cata-
lytic domain to catalytically inactive Cas9 (dC9-D3A), have aimed to alter DNA methylation at desired loci. Here, we
show that these tools exhibit consistent off-target DNA methylation deposition in the genome, limiting their capabilities
to unambiguously assess the functional consequences of DNA methylation. To address this, we developed a modular
dCas9-SunTag (dC9Sun-D3A) system that can recruit multiple DNMT3A catalytic domains to a target site for editing
DNAmethylation. dC9Sun-D3A is tunable, specific, and exhibits much higher induction of DNAmethylation at target sites
than the dC9-D3A direct fusion protein. Importantly, genome-wide characterization of dC9Sun-D3A binding sites and
DNAmethylation revealed minimal off-target protein binding and induction of DNAmethylation with dC9Sun-D3A, com-
pared to pervasive off-target methylation by dC9-D3A. Furthermore, we used dC9Sun-D3A to demonstrate the binding
sensitivity to DNA methylation for CTCF and NRF1 in situ. Overall, this modular dC9Sun-D3A system enables precise
DNA methylation deposition with the lowest off-target DNA methylation levels reported to date, allowing accurate func-
tional determination of the role of DNA methylation at single loci.
[Supplemental material is available for this article.]
DNAmethylation has been shown to play a critical role in develop-
ment and pathogenesis of various disease states and is frequently
associated with transcriptional repression (Li et al. 1992; Okano
et al. 1999; Jackson-Grusby et al. 2001; Egger et al. 2004; Bernstein
et al. 2007; Smith and Meissner 2013; Perino and Veenstra 2016;
Gao andTeschendorff 2017). In recent years, single base resolution
methylome maps have been generated for different cell types and
organisms, providing insights into the many possible functions of
DNA methylation in the genome (Cokus et al. 2008; Irizarry et al.
2009; Lister et al. 2009, 2013; Maunakea et al. 2010; Stadler et al.
2011). Although comparative analyses of DNA methylation pat-
terns with other genomic data such as transcription factor (TF)
binding, gene expression, and chromatin state have been used to
infer the functions of this DNA modification, these techniques
only provide correlative information. Therefore, a growing body
of research is aimed at disentangling the cause or consequence of
gene repression by DNA methylation, including its potential role
in the shaping of the TF binding landscape.
Traditional approaches to directly assess the relationship be-
tween CG methylation (mCG) within TF binding motifs and the
occupancy of potentially mCG-sensitive TFs have relied on either
the artificial insertion of DNA sequences that contain a TF binding
motif with differingmCG states, biochemical experiments leverag-
ing gel shift properties, pharmacological inhibition, or genetic per-
turbation of DNAmethyltransferases (DNMTs) (Renda et al. 2007;
Stadler et al. 2011; Maurano et al. 2015). DNMT inhibitors, such as
5-azacytidine, were previously used to alter DNA methylation
states and infer the influence upon TF binding (Wang et al.
2012; Maurano et al. 2015). However, these pharmacological in-
hibitors of DNMTs alter the DNAmethylation landscape globally,
induce broad transcriptional changes, and result in highly pleio-
tropic off-target effects. Therefore, these are not suitable to
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understand the nuanced impact of DNA methylation on TFs at
specific binding sites. More recently, a systematic evolution of li-
gands (methylated and unmethylated short double stranded
DNA) by exponential enrichment (SELEX)–based investigation
of the effect upon TF binding capacity in vitro of mCG in the
core DNA-binding site for hundreds of TFs and TF binding do-
mains revealed that the majority of TFs are sensitive to mCG, re-
sulting in either increased or reduced DNA-binding affinity (Yin
et al. 2017). However, in vitro binding assays lacking the native
chromatin context and the artificial insertion of DNA sequences
cannot accurately recapitulate an actual biological process, while
pharmacological and genetic perturbations of DNMTs cause unde-
sired global depletion of mCG. Thus, these techniques suffer from
confounding secondary effects due to a lack of target selectivity
and are therefore unable to accurately address the role of mCG
in regulating mCG-sensitive TF binding. Therefore, there is a
need to develop epigenome editing tools that can achieve targeted
and highly specificmodulation ofmCG states at TF bindingmotifs
in order to clarify the roles of mCG in shaping the mCG-sensitive
TF occupancy landscape.
A major challenge has been the development of precise,
adaptable tools that are capable of directing targeted DNAmethyl-
ation to individual loci in different genomic contexts. Advances
have been made by directly fusing DNMT enzymes (e.g., the de
novo mammalian DNMT 3a [DNMT3A] or the prokaryotic CG
methyltransferase, M.SssI/MQ1) to programmable DNA-binding
domains, including zinc fingers, transcription activator-like effec-
tors (TALEs), and deactivated Cas9 domains (dCas9) to induce
targeted deposition of DNA methylation (Rivenbark et al. 2012;
Siddique et al. 2013; Nunna et al. 2014; Bernstein et al. 2015; Stol-
zenburg et al. 2015; Amabile et al. 2016; Liu et al. 2016; McDonald
et al. 2016; Ford et al. 2017; Lei et al. 2017;O’Geen et al. 2017; Step-
per et al. 2017; Xiong et al. 2017). Thus, in theory, it is now possi-
ble to examine context-dependent transcriptional changes in
response to localized epigenomic changes, but this varies greatly
between target sites and DNA-binding domains (Jurkowski et al.
2015; Köferle et al. 2015). Furthermore, we currently understand
very little about the off-target effects of these systems upon meth-
ylation throughout the genome. Given the importance of target
specificity to these systems, gaining a comprehensive understand-
ing of specificity, and developing approaches to improve it, is
critical for the implementation and progression of accurate epige-
nome engineering.
Recently, attempts at investigating TF occupancy and mCG
binding sensitivity have focused on the CCCTC-binding factor
(CTCF), a TF involved in DNA looping and chromatin architec-
ture (Phillips and Corces 2009; Hashimoto et al. 2017). These stud-
ies have utilized direct fusion constructs between dCas9 and
DNMT3A (Liu et al. 2016) or M.SssI (Lei et al. 2017). The latter
achieved highly specific, but only low level, induction of methyl-
ation at a limited number of CG sites across their target region (Lei
et al. 2017), while the former attained higher levels ofmethylation
induction but also reported off-targetmethylation (Liu et al. 2016).
This suggests limited versatility and specificity of these single fu-
sion constructs, despite both studies reporting reducedCTCFoccu-
pancy upon changes inmCG state. Furthermore, only recently has
attention begun to be paid to potential off-target DNA methyla-
tion or demethylation delivered by these epigenome editing tools,
with widespread off-target effects being observed (Galonska et al.
2018; Liu et al. 2018), but no satisfactory solution to this problem
has been reported so far. Hence, it is paramount to study the sen-
sitivity of TF binding to methylated DNAwithin their native chro-
matin context at endogenous loci, with the highly precise targeted
DNAmethylation editing. Here, we describe the development and
comparative analysis of dCas9-based epigenome editing systems
that recruit the catalytic domain of DNMT3A, with a particular fo-
cus on comprehensive assessment and minimization of off-target
binding and DNA methylation induction, and utilization of opti-
mized systems for modulating TF binding.
Results
Direct fusion of dCas9 to the DNMT3A catalytic domain results
in high off-target DNA methylation
The direct fusion of dCas9 to the catalytic domain of DNMT3Awas
previously reported and used to induce cytosine methylation at
targeted loci (Qi et al. 2013; Amabile et al. 2016; Liu et al. 2016;
Vojta et al. 2016; Stepper et al. 2017). However, the potential off-
target binding and methylation induced by these constructs has
not been comprehensively assessed. In order to better understand
the on-target and off-target effects of this system,we generated two
dCas9-DNMT3A constructs, dC9-D3A and dC9-D3A-high (Fig.
1A), where the sole difference was in their puromycin selection
marker. While identical in their structural design, dC9-D3A-high
had the puromycin N-acetyltransferase fused to a self-cleavable
peptide (P2A) (Kim et al. 2011), whereas the dC9-D3A construct
had the puromycin-selectable gene expressed via its own constitu-
tive promoter. MCF-7 cells or HeLa cells were transiently transfect-
ed with these two constructs and a gRNA targeting the UNC5C
promoter and incubated for 48 h to allow for adequate protein ex-
pression followed by 48 h puromycin selection. Cells were then
harvested, and DNA or chromatin was extracted for targeted bisul-
fite sequencing (targeted bsPCR-seq), chromatin immunoprecipi-
tation (ChIP), or ChIP bisulfite sequencing (ChIP-bs-seq) (Fig.
1B; Brinkman et al. 2012). Initially wemeasured induced on-target
DNA methylation at the UNC5C promoter and a proxy for poten-
tial off-target DNA methylation at the promoters of the BCL3 and
DACH1 genes (Fig. 1C) in HeLa cells with dC9-D3A or dC9-D3A-
high. Surprisingly, dC9-D3A exhibited poor on-target DNA meth-
ylation induction at the UNC5C promoter, with the highest ob-
served increase in methylation at any single CG site within the
region of 21%, and an average ΔmCG increase of 5% over all 62
CGs in the region. In contrast, dC9-D3A-high induced DNAmeth-
ylation up to 52% at single CG sites in the UNC5C promoter and
an average ΔmCG increase of 16% over the promoter region.
However, dC9-D3A-high displayed strong off-target DNA methyl-
ation activity compared to dC9-D3A at the BCL3 promoter (aver-
age increase of 3% and 0.8%, respectively, over 46 CGs) but less
so at the DACH1 promoter (average increase of 1.6% and 1.4%, re-
spectively, over 48 CGs) (Fig. 1C).We speculated that the different
on- and off-target DNA methylation rate was the result of sgRNA
design as well as differing protein levels of dC9-D3A and dC9-
D3A-high. Indeed, western blot on protein extracts from cells be-
fore and after puromycin selection demonstrated that protein lev-
els were substantially higher in cells transfected with dC9-D3A-
high compared to dC9-D3A, regardless of selection (Fig. 1D). We
consequently reasoned that modulating the on- and off-target ef-
ficiency for targeted DNAmethylation could not be accomplished
by merely changing expression levels of the direct fusion con-
structs and that there was an inherent tradeoff in the on-target
methylation efficacy versus off-target methylation with the direct
fusion system. A redesigned, modular system for independent
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recruitment of theDNMT3A effectormay be effective for overcom-
ing this shortcoming (Fig. 1A).
Adapting a modular dCas9 system for achieving high and specific
DNA methylation
Amodular dCas9 systemhas previously been reported utilizing the
SunTag array (Tanenbaum et al. 2014). This repeating array of
short repeat peptide sequences is fused to dCas9, thus acting as
an epitope docking station that allows multiple proteins (fused
to the counterpart single-chain antibody, scFv-GCN4, subse-
quently referred to as αGCN4) to be recruited to a desired target
site. We hypothesized that this system would allow us to indepen-
dently modulate the expression of the DNMT3A catalytic domain
and the dCas9-SunTag, with the aim of limiting dCas9-SunTag
abundance to favor its binding to its highest affinity sites in the ge-
nomewhile restricting the presence of excess DNMT3A in order to
avoid its nonspecific activity. Such a system should reduce
A B
C
D
Figure 1. Characterizing on-target and off-target mCG deposition efficiency by dC9-D3A direct fusion system. (A) Schematics of the dCas9 (dC9) and
TALE (T) constructs used, indicating positioning of nuclear localization sequences (NLS), protein tags (human influenza hemagglutinin [3xHA, 3xTy1]),
promoter choice (glycerol kinase promoter [hPGK], human elongation factor-1 alpha promoter [hPEF1a]), solubility tag (protein G B1 domain [GB1]),
selectable marker (puromycin resistance [puro]), single-chain Fv antibody against GCN4 domain (αGCN4), and human DNTM3A catalytic domain
(D3A). (B) Timeline and outline for experimental design for measuring DNA methylation and TF occupancy (CTCF and NRF1). (C) Targeted DNA meth-
ylation deposition to the UNC5C promoter in HeLa cells, measured by bsPCR-seq. sgRNA placement is shown with yellow arrows; dotted lines indicate
interval for CGs included in quantitation. (D) Western blot of relative dC9-D3A protein abundance (anti-Ty1) per 50 µg of total cell lysate: (lane 1) untrans-
fected HeLa cells, (lanes 2,4) 48 h post transfection (hpt), (lanes 3,5) 48 hpt and 48 h puromycin (puro) selection, loading control anti-Tubulin. Arrow
indicates dC9-D3A.
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spurious off-target DNA methylation while maintaining high on-
target mCG induction, thus improving on the design of the dCas9
molecule directly fused to a single DNMT3A. We adapted the pre-
viously reported SunTag system by fusing 10 GCN4 peptides with
a flexible linker to dCas9 (dC9Sun) and the counterpart antibody
to DNMT3A (αGCN4-D3A; dC9Sun-D3A) (Fig. 1A). The resulting
dual constructs were tested in a titration series (Fig. 2A) that aimed
tomaximize on-target DNAmethylation deposition at the UNC5C
promoter, while minimizing off-target DNA methylation induc-
tion. The BCL3 promoter was used as an initial reporter locus for
detecting the induction of excessive off-target DNA methylation.
The entire set of transfections was carried out in HeLa cells that
were transfected with a fixed amount of pGK-dCas9-SunTag plas-
mid and varying amounts of effector (αGCN4-D3A). The latter
was titrated from 0% to 33% of the total amount of DNA transfect-
ed. The optimum amount of pEF1a-αGCN4-D3A effector that
yielded the highest amount of on-target DNA methylation and
the least amount of off-target DNA methylation was determined
to be 4% of the total amount of DNA transfected. The change in
DNAmethylation (ΔmCG) was calculated by subtracting the aver-
age of all mCG/CG ratios in a defined region (e.g., 62 CGs at the
UNC5C promoter) from the same CG sites in control-treated cells
(baseline). Our adapted system was able to achieve high on-target
mCGdeposition of up to 49%at individual CpGdinucleotides and
an average ΔmCG of 12.6% over all 62 CG dinucleotides, while
maintaining off-target DNA methylation at only 0.7% (Fig. 2A,
green highlight). A complementary experiment that titrated the
amount of pGK-dCas9-SunTag plasmid while maintaining a fixed
αGCN4-D3A effector quantity did not substantially improve on-
target DNA methylation in HeLa cells, but altering the dC9Sun
to effector ratio might be beneficial for other cell types (Supple-
mental Fig. S1). Hereafter, the optimized ratios of pGK-dCas9-
SunTag plasmid to pEF1a-αGCN4-D3A effector plasmid from
Figure 2A were used for the remainder of the study and will be col-
lectively referred to as dC9Sun-D3A. The use of the SunTag system
to recruit DNMT3A via TALEs to the DACH1 and UNC5C promot-
ers also substantially improved on-target mCG deposition com-
pared to a TALE-DNMT3A single fusion (Supplemental Figs. S2,
S3). However, while TALEs are known for their high specificity,
they are time consuming to adapt formultiple target sites and chal-
lenging to multiplex; hence, we focused on the more rapidly con-
figurable dCas9 system for the remainder of the study.
To control for changes in methylation due to the presence of
dCas9 binding in the vicinity of our targeted region, we initially
used a catalytic mutant of the DNMT3A catalytic domain
(D3AMut), which harbored four alanine substitutions in its cata-
lytic center (F39A, E63A, E155A, R284A). However, when mCG
deposition was tested at three target sites (CCDC85C intron, SHB
intron, andMIR152) (Supplemental Fig. S4A–C), we detected resid-
ual mCG deposition of up to 22%, 16%, and 8%, respectively. We
speculate that the DNMT3A catalytic domain might be able to re-
cruit endogenous functional WT DNMT3A by forming oligomeric
complexes as previously described (Holz-Schietinger et al. 2011).
Accordingly, to eliminate any potential functional impacts based
on residual induction of cytosine methylation, we determined
that an αGCN4-mCherry effector would be a more appropriate
control for the effect of dCas9 binding alone, compared to the
αGCN4-D3AMut construct.
Targeting of theUNC5C promoterwas repeatedwith dC9Sun-
D3A, dC9-D3A, and dC9-D3A-high to compare the performance of
each system, measuring the methylation level at CpG dinucleo-
tides surrounding the UNC5C target region as well as at the BCL3
promoter, which served as a proxy for widespread off-target DNA
methylation (Fig. 2B). dC9Sun-D3A induced mCG at the UNC5C
promoter to comparable levels as dC9-D3A-high (ΔmCG over 62
CG sites at UNC5C was 4%, 15%, and 13% for dC9-D3A, dC9-
D3A-high, and dC9Sun-D3A, respectively), without the shortcom-
ings of promiscuous off-target methylation (ΔmCG over 46 CG
sites at the off-target BCL3 region was 1.2%, 4.4%, and 0.6%
for dC9-D3A, dC9-D3A-high, and dC9Sun-D3A, respectively).
Notably, the off-target mCG induction by dC9Sun-D3A was re-
duced by >80% compared to dC9-D3A-high (Fig. 2B, BCL3 pro-
moter off-target methylation).
To determine whether this improved DNA methylation in-
duction and reduced off-target effects are achievable at multiple
different loci, the set of target sites was expanded both indepen-
dently and via multiplexed targeting. This was achieved by select-
ing a series of CTCF sites that were previously shown to be mCG
sensitive (Maurano et al. 2015), hypomethylated, and occupied
by CTCF in HeLa cells. Notably, high mCG induction was consis-
tently achieved across both CTCF core binding sites (CCDC85C in-
tron [47%] and SHB intron [44%]) and theUNC5C promoter (17%)
(Fig. 2C, row 2–4). Multiplexing all three single guide RNAs
(sgRNAs) resulted in a loss of on-target mCG deposition of <5% at
all three targets (Fig. 2C, highlighted regions, cf. rows 2–4 and
row 5), strongly suggesting that the dC9Sun-D3A system is a viable
multiplexing option for mCG deposition. The maximum ΔmCG
observed was at the UNC5C promoter, with a 57% increase.
dC9Sun-D3A was able to induce DNA methylation at distances
≥300bp;however, the SunTag systemdidnot appear to addanyad-
ditional distance compared to the dCas9 direct fusion (Supple-
mental Fig. S5). The same was observed when the T-D3A direct
fusion is compared to TSun-D3A; however, adding the SunTag sys-
tem to aTALEdomain targeting theUNC5Cpromoter improves on-
target mCG deposition from 30% to 64% (Supplemental Fig. S5).
Furthermore, we investigated whether a similar dC9Sun sys-
temwas able to facilitate DNAdemethylationwhen coupled to hu-
man TET1 (tet methylcytosine dioxygenase 1) catalytic domain
(Morita et al. 2016) at the GAD1 intron 3. We found that the effi-
cacy of the systemwas highly dependent on the sgRNAplacement,
with dC9Sun-TET1 achieving up to 60.0% mCG reduction at the
GAD1 intron 3 (Supplemental Fig. S6). Taken together, the system
of dC9Sun in combination with epigenetic effectors coupled to
αGCN4 is highly effective in targeted deposition or removal of
DNA methylation, without the limitations of high off-target
effects.
Global assessment of binding and methylation specificity
In order to more comprehensively assess the specificity of the
dC9Sun-D3A system, we performed ChIP-seq upon dC9Sun using
the 3xHA epitopes present at the N terminus of the protein, after
targeting the construct to intron 1 of SHB (Fig. 3A). ChIP-seq
peak calling identified 13 significant peaks throughout the entire
genome (q-value < 0.01), with the top 10 most significant peaks
shown in Figure 3A. All but one off-target peak were found to
have <10% of the ChIP-seq normalized read density compared to
the on-target binding site peak in the SHB intron (Supplemental
Table S1). The reciprocal αGCN4-D3A ChIP-seq experiment using
the C-terminal 3xTy1 epitope yielded only one significant peak at
the on-target SHB site (Supplemental Table S1).
To further explore the extent of off-target mCG deposition
and dC9Sun-D3A occupancy, we designed all three components
of the system (dC9Sun, αGCN4-D3A, and SHB sgRNA) to express
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different fluorescent proteins (BFP, GFP, and mCherry, respective-
ly), so that cells transfected with all three constructs could be en-
riched using flow cytometry (Supplemental Fig. S7A). The cell
sorting approach, enriching for cells that have an intermediate lev-
el of expression of dC9Sun (BFP coexpression) and αGCN4-D3A
(GFP fusion), was chosen to first guarantee expression of all three
components (dC9-Sun, αGCN4-D3A, and sgRNA) in a single cell,
and second, to achieve the highest possible on-targetedmCG dep-
osition at SHB promoter while keeping off-target mCG change to a
minimum (Supplemental Fig. S7B). Next, targeted bsPCR-seq in
A
C
B
Figure 2. Modular dC9Sun-D3A system outperforms dC9-D3A direct fusion. (A) Titration of αGCN4-D3A effector (D3A [human DNMT3A catalytic
domain]). Fraction of mCG is shown in black bars; dotted lines and black arrows indicate region used to calculate mCG change. (B) Comparison of
dC9-D3A high, dC9-D3A, dC9Sun-D3A, and dC9Sun-mCherry (CRISPRi control) at theUNC5C promoter (on-target) versus the BCL3 promoter (off-target)
by targeted bsPCR-seq (averagemCG/CG, n = 3 replicates; error bars, SD). (C ) mCGdeposition efficiency by dC9Sun-D3A at three different loci (CCDC85C,
SHB, and UNC5C promoters) measured by targeted bsPCR-seq (average mCG/CG, n = 3 replicates; error bars, SD).
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these sorted cells was performed for off-target sites and the on-tar-
get site SHB intron. Of all the off-target ChIP peaks, only three ex-
hibited an increase in DNA methylation of ΔmCG >10% at one or
more underlying CG dinucleotides (off-target peak regions 1, 3,
and 9) (Fig. 3A), possibly driven by the hypomethylated state of
these loci. A plausible explanation for the off-target binding of
dC9Sun-D3A to these sites is that they contain partial matches
to the SHB sgRNA, with the matching bases ranging from 11–15
nt out of the 17 nt of the SHB sgRNA target sequence (Supplemen-
tal Fig. S8). Therefore, the specificity of this system is likely only re-
stricted by the uniqueness of the genomic sequence to which
dCas9 is targeted and could be improved by alternative sgRNA de-
sign. Overall, these results demonstrate that the dC9Sun-D3A sys-
tem can exhibit very high specificity of binding in the genome.
While binding of dC9Sun-D3A appeared to be highly specific,
there is the potential that expression of the components of the sys-
tem could still induce off-target methylation without detectable
binding of dC9Sun-D3A. Therefore, to identify any mCG changes
more broadly throughout the genome, the Illumina TruSeq meth-
yl capture EPIC kit was used for targeted capture and detection of
the DNA methylation state at single-base resolution (target solu-
tion capture bisulfite sequencing [TSC-bs-seq]) for 2.6 million
CpG sites located in genomic regulatory regions in the DNA isolat-
ed from the previously fluorescently sorted cells (Supplemental
Fig. S7). This approach allows quantitation of the DNA methyla-
tion state of∼12%of all CGs present in the human genome, which
are specifically targeted to cover the majority of known constitu-
tively or conditionally unmethylated and lowly methylated re-
gions in the genome (97% of CpG islands, 95% GENCODE
promoters, 66% open chromatin regions, 98% FANTOM5 enhanc-
ers, 78% TF binding sites). Therefore, this provides an effective ap-
proach for high coverage (≥5 reads per CG and replicate) base
resolution detection and quantitation of potential off-targetmeth-
ylation in the regions of the genome that could potentially be-
come methylated. These probes captured regions including the
on-target SHB intron and off-target site 9, where up to 80.5%
and 82.1% methylation was observed, respectively, as observed
in the targeted bsPCR-seq analysis (Supplemental Fig. S9). Notably,
on-target mCG deposition was measured independently to be
80.5% and 78.0% for the CGs in the CTCF binding site (SHB in-
tron) by either TSC-bs-seq or targeted bsPCR-seq, respectively.
The methylation levels quantitated at CG sites by both targeted
bsPCR-seq and TSC-bs-seq methods were very similar to each oth-
er, with Spearman correlation coefficient for controls and dC9Sun-
D3A treatment of r = 0.976 and r = 0.967, respectively (total num-
ber of CGs = 94, n = 3 replicates). Furthermore, both sets of mea-
surements suggest that sorting cells for optimal expression of all
three components (dC9Sun, αGCN4-D3A, and sgRNA) reduces
off-target mCG deposition by 2.1-fold (UNC5C promoter) and im-
proves on-target mCG deposition in the cell population by 17.3%
compared to puromycin selection (Supplemental Fig. S10). The
high specificity of targeted DNA methylation induction by the
dC9Sun-D3A systemwas further demonstrated by the very similar
mCG levels (Pearson correlation coefficient r = 0.9867) at the
2,629,232 CGs covered (depth ≥5 reads; median CG coverage
≥16) throughout the targeted regions of the genome between cells
expressing the control construct (dC9Sun-mCherry) and those ex-
pressing dC9Sun-D3A and the SHB intron 1 sgRNA (Fig. 3B). This
was also observed for all pairwise correlations of each replicate
(Supplemental Fig. S11). Moreover, the difference in average
A B
C
Figure 3. Genome-wide off-target DNAmethylation assessment. (A) Compilation of dC9Sun-D3AChIP-seq (blue peaks) and targeted bsPCR-seq for CGs
covered by ChIP-seq (bsPCR amplicon location in red), bsPCR-seq mCherry-only expressing cells (black line), and SHB sgRNA + dC9Sun-D3A (orange line)
(sorted cells, n = 3 biological replicates; error bars, SD). (B) Correlation of mCG values for each CG site (>2.6 × 106, ≥5× coverage) of combined replicates
(n = 3) from Illumina TruSeqmethyl capture EPIC pulldown experiment. mCherry (baseline) HeLa cells shown on y-axis; SHB target dC9Sun-D3A HeLa cells
shown on x-axis. Pearson correlation coefficient shown in upper left corner. (C) Boxplot of mCG/CG from all covered CGs from mCherry only HeLa cells
(gray) and SHB sgRNA + dC9Sun-D3A (orange) (n = 3 biological replicates; thick black line indicates median; error bars, SD).
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fraction mCG/CG for all CGs covered (≥5 reads coverage,
2,629,232 CGs, n = 3 replicates) between cells expressing the con-
trol construct (dC9Sun-mCherry) and those expressing dC9Sun-
D3A and the SHB intron sgRNA was <0.3% (Fig. 3C). Overall,
this demonstrates that the dC9Sun-D3A system exhibits very
high specificity in both binding sites and induction of DNAmeth-
ylation, in stark contrast to the high off-target activity of dC9-D3A
(Figs. 1C, 2B), the system that has been most commonly used to
date (Amabile et al. 2016; Liu et al. 2016; Vojta et al. 2016).
Direct assessment of the effect of DNA methylation
on DNA–protein interactions
Having established the specificity and efficiency of the dC9Sun-
D3A system, we sought to examine the consequences of targeted
mCG deposition upon binding of methylation sensitive TFs.
Previously, Maurano et al. (2015) reported that a subset of CTCF
binding sites are sensitive to mCG reduction, induced by either
DNMT triple knockout in HCT116 cells or 5-azacytidine treatment
in K562 cells. Based on these findings, we speculated that CTCF
binding sites sensitive tomCG loss would exhibit a reciprocal phe-
notypewhenmCGwas specificallydeposited inCTCFcorebinding
sites inHeLa cells. To that end,we selected target regions for testing
by intersecting the CTCF binding sites that were mCG sensitive in
bothK562andHCT116 sites (FDR < 0.01)withCTCF sites occupied
in HeLa cells. These sites were further required to each contain
at least one hypomethylated CG in their core binding site. Three
resulting CTCF binding sites were selected, in (1) a SHB intron,
(2) a region upstream ofMIR152, and (3) a CCDC85C intron. CTCF
binding sites for MIR152, SHB intron, and CCDC85C intron are
completely unmethylated in HeLa cells, as determined by whole-
genome bisulfite sequencing (WGBS) (Fig. 4A,B; Supplemental
Fig. S12,HeLaWGBS track). This observationwas confirmedby tar-
geted bsPCR-seq,where the amplicon covered the entire CTCFcore
binding site (Fig. 2C, baseline panel,CCDC85D and SHB). Next, we
targeted mCG to the CTCF core binding sites by recruiting either
dC9Sun-D3A or dC9Sun-D3AMut with sgRNAs binding within
100 bp of the CTCF core binding site. dC9Sun-D3AMut was
used to control for possible steric hindrance effects on CTCF bind-
ing; however, we subsequently utilized dC9Sun-mCherry since
dC9Sun-D3AMut exhibited residual DNA methylation activity
(Supplemental Fig. S4). After 48 h of puromycin selection, the
on-target mCG deposited at the CTCF core binding sites was 62%
for the single CG in the CTCF binding site in SHB (Fig. 4C), 31%
and 46% for the two CGs in the CTCF binding site upstream of
MIR152 (Fig. 4D), and 52% and 35% for the two CGs in the CTCF
binding site inCCDC85C (Supplemental Fig. S12B).We then inves-
tigated whether CTCF binding was impacted by the targeted DNA
methylation deposited in its core binding site by performingCTCF
ChIP-seq in duplicates for each condition. Importantly, all three
CTCF binding sites, which were independently targeted by
dC9Sun-D3A, showed a significant decrease in CTCF occupancy
compared to dC9Sun-D3AMut (0.39-fold, 0.35-fold, and 0.67-
fold reduction in normalized ChIP-seq read density for SHB,
MIR152, and CCDC85C, respectively (edgeR, FDR = 2.6 × 10−3,
1.9 × 10−5, 5.2 × 10−12, respectively). Notably, the reduction in
CTCF binding at the targeted loci (MIR152, SHB, and CCDC85C)
were ranked either the most or secondmost decreased CTCF peaks
compared to control, as determined by edgeR analysis of normal-
ized peak counts (for SHB, see Fig. 4E; for MIR152, see Fig. 4F; for
CCDC85C, see Supplemental Fig. S12C). Further, we performed
CTCF ChIP-bisulfite sequencing (ChIP-bs-seq) (Brinkman et al.
2012;Hon et al. 2012; Stathamet al. 2012) to assess theDNAmeth-
ylation status of theDNA thatwas directly boundbyCTCF (Fig. 4A,
B; Supplemental Fig. S12A). This confirmed that theDNAboundby
the remaining CTCFwasmethylated and comparable to the initial
on-target DNA methylation measured by targeted bsPCR-seq (Fig.
4C,D, top panel comparing gray to colored circles), suggesting
that CTCF occupancy is reduced by >30% for all three CTCF target
sites (SHB,MIR152, andCCDC85C) due tomCGdeposition. The re-
maining chromatin-bound CTCF was found to have mCG in its
core binding, indicating a possible transition state where CTCF
is either poised to leave or mCG is targeted for active DNA
demethylation.
To extend the findings of targeted mCG deposition on CTCF
binding to an additional TF, we next investigated the impact of
mCG deposition on the binding of NRF1. This TF was selected as
previous studies have found that NRF1 binding appears to be
DNAmethylation sensitive in vitro, as determined by a differential
array binding assay (Hu et al. 2013), as well as in cell culture, where
NRF1 occupies binding sites that lose mCG in DNMT triple knock-
out embryonic stem cells (Domcke et al. 2015). Similarly to our
CTCF analyses, we set out to target four NRF1 occupied binding
sites in HeLa cells, with each having at least one hypomethylated
CG in the core binding site (TMEM206 promoter, downstream
from TRAPPC3, upstream of MSANTD3, and downstream from
TEF) with six different sgRNAs each. These targets were chosen
based on both strong NRF1 occupancy as well as having narrow
hypomethylated binding sites, where methylation was found
within a 1-kb window both upstream of and downstream from
the NRF1 binding site. As noted before (Hinz et al. 2015; Moreno-
Mateos et al. 2015; Horlbeck et al. 2016) and seen in the resulting
on-target DNAmethylation patterns, sgRNA placement greatly af-
fected the extent of mCG induced by dC9Sun-D3A (Supplemental
Fig. S13A–D). Consequently, we focused solely on the TMEM206
promoter as it showed the greatest susceptibility to targeted mCG
induction based on the presence of three CGs in its 15-bp core
NRF1 binding site and appeared to be strongly occupied by NRF1
(Fig. 5A). To maximize on-target DNA methylation deposition for
all threeCGs,wechose sgRNA2 for all furtherexperiments (Supple-
mental Fig. S13A). Next we performed targeted bsPCR-seq to mea-
sure the average DNA methylation induction for all puromycin
selected cells and found a 30%, 32%, and 32% increase in methyl-
ation level for each of the three CGs in the TMEM206 core binding
site, respectively (Fig. 5B). As with our CTCF analyses, we then test-
ed whether NRF1 could also bind to methylated DNA at the
TMEM206 promoter by performing NRF1 ChIP-bs-seq. Due to the
very low quantity of NRF1-immunoprecipitated DNA as the result
of fewer NRF1 binding sites in the genome compared to other
DNA-bindingproteins suchasCTCF,wemergeddata frommultiple
replicates (n = 3) to gain sufficient coverage to accurately quantitate
mCG levels in the NRF1 core binding site. The NRF1 core binding
site and CGs upstream of and downstream from it are completely
hypomethylated as judged by bsPCR-seq and NRF1 ChIP-bs-seq
when dC9Sun-mCherry is recruited to the TMEM206 promoter
(Fig. 5B, lower panel). When TMEM206 promoter was targeted by
dC9Sun-D3A, no mCG was detectable in the ChIP-bs-seq data of
the NRF1 core binding site (Fig. 5B); however, upstream of this
binding site, mCGwas still detectable to the same level as seen pre-
viously in the targeted bsPCR-seq (Fig. 5B). This observation sug-
gested that mCG was only tolerated upstream of the NRF1
binding site. Consequently, NRF1 either blocked mCG deposition
in its core binding site or lost its binding capacity once mCG was
deposited by dC9Sun-D3A. To understand the impact on NRF1
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binding, we performed NRF1 ChIP-seq and found that NRF1 bind-
ing is reduced by 30% (edgeR, FDR = 0.0085, ranked 63 out of 607)
when targeted by dC9Sun-D3A compared to cells targeted by
dC9Sun-mCherry (Fig. 5C). Furthermore, while dC9Sun-D3A
may have the potential to recruit other factors that cause the ob-
served reduction in NRF1 binding, this would not be consistent
with the observed DNAmethylation pattern of NRF1-bound DNA
as measured by ChIP-bs-seq (Fig. 5B). Notably, when DNA
A B
C D E F
Figure 4. Impact of targeted DNAmethylation induction on CTCF binding. (A) Genome Browser display of targeted CTCF binding site in an SHB intron.
Sets of experiments include (from top to bottom): targeted bsPCR-seq (fraction mCG/CG), CTCF-ChIP-bs-seq (fraction mCG/CG), CTCF-ChIP-bs-seq cov-
erage, and CTCF ChIP-seq coverage. CTCF core binding site is highlighted in shaded green. CTCF ChIP-seq coverage (TMM normalized counts) is shown
with adjacent peaks for reference (broken x-axis). Red dotted line is set to maximum targeted CTCF peak in the control samples. (B) Genome Browser snap-
shot of targeted CTCF binding site upstream ofMIR152. (C,D) Quantitation of mCG/CG in CTCF core binding site (green shaded region) and adjacent to
core binding site comparing targeted bsPCR-seq (gray circles) to ChIP-bs-seq (purple or green circles for αGCN4-D3A and yellow circles for αGCN4-
D3AMut) for SHB and MIR152, respectively (replicates n = 2; error bars, SD; Fisher’s exact test). (E,F) Quantitation of CTCF CPM normalized ChIP-seq
peak at SHB and MIR152, respectively (replicates n = 2; error bars, SD; statistic edgeR, Benjamini-Hochberg multiple test corrected P-values).
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methylation was targeted to the NRF1 core binding site in the
TMEM206 promoter, in both HeLa and HEK293T cells, TMEM206
transcript abundance was decreased, suggesting that the DNA
methylation–dependent loss of NRF1 binding to the TMEM206
promoter appears to be causative for a change in transcription
(Fig. 5D).
To compare the different levels of CTCF andNRF1DNAmeth-
ylation tolerance, core binding sites in the genome were interro-
gated by extracting the position of CGs in each core binding site
(CTCF and NRF1 positional weight matrix) followed by averaging
mCG/CG levels at all CG sites within each core binding site of
CTCF and NRF1 ChIP-bs-seq data. Further, we parsed the average
level of mCG/CG per core binding site for CTCF and NRF1 into
bins based on the average mCG level (TF bindingmotif mCG level
<5%, 5%–10%, 10%–50%, and >50%) (Fig. 5E), where 94.8% (799
out of 843) of NRF1 binding sites genome-wide have DNAmethyl-
ation levels <5%. In contrast, only 69.6% (10,501 out of 15,077) of
CTCF binding sites have DNAmethylation levels <5%, whichmay
explain why we detected that CTCF could bind to its core binding
site even after targeted DNA methylation induction by dC9Sun-
D3A (Fig. 4C,D). Taken together, we show that targeted DNA
methylation, but not dCas9 interference (Figs. 4C,D, 5B), dis-
placed both CTCF and NRF1, with the latter showing the higher
DNA methylation sensitivity. Future work could leverage precise
mCG deposition of the dC9Sun-D3A system to test direct mCG
sensitivity for a variety of TFs in vivo.
Discussion
Previouswork has highlighted the ability of dCas9 to be used to in-
duce DNAmethylation at desired regions in the genome (Amabile
et al. 2016; Liu et al. 2016; Vojta et al. 2016; Lei et al. 2017; Stepper
et al. 2017). However, a key issue that to date has not been suffi-
ciently addressed is the potential for off-target DNA methylation
induction, which could lead to nonspecific genomic responses
and limits the utility of the systems for unambiguous assessment
A B
C
D E
Figure 5. Impact of targeted DNA methylation induction on NRF1 binding. (A) Genome Browser display of the targeted NRF1 binding site in the
TMEM206 promoter. Sets of experiments include (from top to bottom): bsPCR-seq (mCG/CG), NRF1-ChIP-bs-seq (mCG/CG), NRF1-ChIP-bs-seq coverage,
and NRF1 ChIP-seq-coverage. The NRF1 core binding site is highlighted in shaded green. (B) Quantitation of mCG/CG in the NRF1 core binding site (green
shaded region) and adjacent to core binding site, comparing targeted bsPCR-seq (gray circles) to ChIP-bs-seq (cyan circles for αGCN4-DNMT3A and yel-
low circles for αGCN4-mCherry) at the TMEM206 promoter (NRF1 ChIP-bs samples combined n = 3 for coverage; bsPCR-seq, n = 3; error bars, SD; statistic:
Fisher’s exact test). (C) Quantitation of the TMEM206 promoter NRF1 ChIP-seq peak counts (TMM normalized) in samples treated with αGCN4-D3A (or-
ange) compared to αGCN4-mCherry (gray) (mCherry n = 2; D3A n = 3; statistic edgeR, Benjamini-Hochbergmultiple test corrected P-values). (D) qRT-PCR
analysis of TMEM206 expression (normalized to geometric mean of the housekeeping genes RPS18, GAPDH, and HSPC3) comparing dC9Sun-D3A and
dC9Sun-mCherry targeted to the NRF1 binding site in the TMEM206 promoter. Cells tested are HEK293T and HeLa cells, respectively (biological replicates
n = 6; reference GFP-Puro transfected, puromycin-treated HeLa or HEK293T cells n = 4; statistic: Wilcoxon/Mann-Whitney U test, one-tailed).
(E) Comparison of average mCG/CG in the CTCF and NRF1 core binding sites, respectively, by binning them into intervals of no (≥0 and ≤0.05), low
(>0.05 and ≤0.1), intermediate (>0.1 and ≤0.5), or high (>0.5) levels of DNA methylation.
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of the effect of DNA methylation at a locus. Single fusion con-
structs, such as dC9-D3A, lack the ability to fine-tune on- versus
off-target DNA methylation deposition, and exhibit extensive
off-target activity. When dC9-D3A expression is increased to
attain high on-target methylation, the off-target methylation
rate reached unacceptably high levels. Conversely, limiting the
expression of the single fusion to reduce off-target methylation
levels resulted in poor induction of on-target DNA methylation.
Therefore, the single fusion constructs presentmultiple significant
deficiencies. Here, we present a highly specific and tunable system
to perform targeted alteration of DNA methylation, based on the
modular SunTag system (Tanenbaum et al. 2014), allowing inde-
pendent variation of the expression of the DNA targeting module
(dC9Sun) and the effector module (αGCN4-D3A). While no sig-
nificant difference in the distance at whichDNAmethylation dep-
osition was observed between the dC9Sun-D3A system and the
direct fusion systems, dC9Sun-D3A exhibited greatly improved
specificity for depositing targeted methylation compared to dC9-
D3A and achieved effective targeting of multiple loci simultane-
ously with on-target DNA methylation induction levels compara-
ble to single-guide experiments. Recently, a similar dC9Sun system
employing full-length DNMT3A1 was described by Huang et al.
(2017), where lentiviral delivery was used. Huang et al. (2017) in-
vestigated off-target mCG deposition by reduced representation
bisulfite sequencing (RRBS) at a limited subset of CpG islands
(about 6100, 21.3% of all possible CpG islands), with a single sam-
ple per condition and reported off-target mCG deposition to be
lower than dC9-D3A direct fusion systems. In contrast, we em-
ployed the more comprehensive approach of using TSC-bs-seq,
covering 2.1million CGs at≥5 reads per sample (∼11× the number
of CGs surveyed inHuang et al. [2017] at equivalent coverage). The
Illumina EPIC TCS-bs-seq system is designed to cover a large
number of putative regulatory regions in the genome that are fre-
quently in an unmethylated state, here covering 12.7% of all
hypomethylated CGs (at ≥5 reads per condition) in the HeLa ge-
nome (∼5.5 × 106 hypomethylated CGs in HeLa genome, mCG/
CG ≤0.2). In contrast, the method used by Huang et al. (2017)
would only cover 1.8% of the hypomethylated CG sites in the
HeLa genome. We found that our system was about 40-fold less
susceptible to gain or loss of mCG at CG islands compared to the
system described by Huang et al. (2017) (Supplemental Fig. S14).
Thus, through well-replicated use of this TCS-bs-seq system, we
have performed one of the most extensive surveys of on- and
off-target methylation induced by dCas9-based DNA methylation
modifying systems to date, demonstrating that our dC9Sun-D3A
system is highly specific.
Having established the specificity and fidelity of our dC9Sun-
D3A system, we subsequently directly determined the impact of
targeted DNA methylation on the binding of two DNA-binding
proteins, CTCF and NRF1. Although CTCF sensitivity to DNA
methylation had previously been reported (Liu et al. 2016; Lei
et al. 2017), our work is the first to directly test the impact of target-
ed DNA methylation deposition upon NRF1 binding. Our results
indicate that both CTCF and NRF1 are impacted by DNA methyl-
ation deposition. CTCF was still able to tolerate and bind methyl-
ated DNA in its core binding site for three independent sites. A
possible explanation for this is that the binding of CTCF is in a
transitional state, where its core binding site has been methylated
but CTCF has yet to be evicted. Alternatively, CTCF may be
binding 5-hydroxymethylcytosine (5hmC), the byproduct of
Tet-mediated oxidation of 5-methylcytosine [5mC]), as previously
described (Feldmann et al. 2013; Teif et al. 2014; Marina et al.
2016) since CTCF ChIP-bs-seq cannot distinguish between 5mC
and 5hmC. In contrast to CTCF, we did not observe NRF1 binding
to any intermediate 5mC or possible 5hmC states, as there was a
loss in NRF1 occupancy upon DNA methylation deposition.
Taken together, the dC9Sun-D3A technology opens up avenues
to perform highly precise DNA methylation deposition and could
be adapted to effectively implement alternative epigenetic editing
such as altering histonemodifications orDNAdemethylationwith
the same advantages as described above. It is also conceivable to le-
verage the array of αGCN4 binding sites on the SunTag for multi-
plexed epigenetic editing, employing more than one epigenetic
effector simultaneously.
Conclusion
The influence of DNA methylation changes on gene regulation is
still a highly debated topic, with broad implications for interpreta-
tion of the potential effect of differential methylation states evi-
dent in a variety of contexts, such as development and cancer.
However, it is paramount to study the effects of targeted DNA
methylation changes at key regions with a high degree of confi-
dence, such that off-target effects by spurious DNA methylation
deposition are minimized. To that end, the dC9Sun-D3A system
described here is highly adaptable and tunable and capable of
high on-target mCG deposition while not suffering from wide-
spread spurious off-target DNAmethylation induction as observed
with some other previously described dCas9 systems. Therefore,
the dC9Sun-D3A system could be employed in a variety of differ-
ent cell types and systems to test the direct effect of mCG deposi-
tion on TF binding, splicing, or transcription in general.
Methods
Cell lines
MCF-7 and HeLa cells were cultured in a humidified cell
culture incubator at 37°C with 5% (v/v) CO2. MCF-7 cells were
maintained using MEM (minimum essential medium) alpha
(Life Technologies, catalog no. 12571071) supplemented with
10% (v/v) fetal bovine serum (FBS) (Integrated Sciences, catalog
no. HYCSV3017603), 1× (v/v) 5.5% sodium bicarbonate (Life
Technologies, catalog no. 25080094), and 1× (v/v) Glutamax
(Life Technologies, catalog no. 35050061) while HeLa cells were
cultured with DMEM (Dulbecco’s modified Eagle’s medium) sup-
plemented with 10% (v/v) FBS and 1× (v/v) Glutamax.
Cell transfections
Transfections were carried out using a 1:3 ratio of DNA to FuGENE
HD (Promega, catalog no. E2311) following manufacturer’s in-
structions. Briefly, MCF-7 or HeLa cells were seeded at 80% conflu-
ency in either six-well culture plate (In-vitro Technologies, catalog
no. FAL353046) or 15-cm culture dishes (In-vitro Technologies,
catalog no. COR430599). Twenty-four hours post seeding, 500
ng of TALE-DNMT3A or dCas9-DNMT3A constructs and 500 ng
of individual sgRNA plasmids were transfected into cells. For the
TALE and dCas9-SunTag constructs, 330 ng was used, along with
330 ng of individual or pooled sgRNAs, 40 ng of αGCN4-
DNMT3A, and 300–320 ng of pEF1a-GFP-Puro (transfection con-
trol plasmid) to make the final amount to 1 µg. This was scaled
up for 15-cm plate transfections. Cells were screened after 48 h
for expression of reporter gene (GFP or mCherry) by fluorescent
microscopy followed by either FACS sorting or 48 h of puromycin
selection (2 µg/mL, Life Technologies, catalog no. A1113803) to
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enrich for positively transfected cells. After puromycin selection,
surviving cells were subsequently either used for ChIPs, ChIP fol-
lowed by bisulfite sequencing, or targeted bisulfite sequencing
where DNA was extracted by the ISOLATE II DNA extraction kit
(Bioline, catalog no. BIO-52067). Triple positive cells containing
the tagBFP2 (dCas9-Suntag vector), mCherry (sgRNA vector),
and sfGFP (αGCN4-DNMT3A vector) were FACS sorted and sub-
jected to DNA extraction using the ISOLATE II DNA extraction
kit (Bioline, catalog no. BIO-52067), which was further used in
determining genome-wide off-target DNA methylation deposi-
tion using the TruSeq methyl capture EPIC library prep kit
(Illumina, catalog no. FC-151-1002) as well as for targeted bisulfite
sequencing.
Plasmid construction
The human codon optimized Cas9 was amplified using PCR from
the hCas9 D10A plasmid (Addgene, 41816). Subsequently, PCR
mutagenesis was conducted to introduce the H840A mutation to
generate the catalytically dead Cas9 (dCas9). The DNMT3A se-
quence was PCR amplified from the ZF-598-DNMT3A plasmid
(gift from Pilar Blancafort) and the N-terminal 3xHA tag, linker
peptide between dCas9 and DNMT3A, and C-terminal 3xTy1 tag
were ordered as separate gBlocks (IDT). Finally, the dCas9 cassette
was inserted into a plasmid backbone containing a puromycin
selectable marker. The single fusion TALE expression vector
backbonewas based on Sanjana et al. (2012), andGibson assembly
(Gibson et al. 2009) was used to replace the nuclease with
DNMT3A. The linker peptide for the TALE-DNMT3A expression
vector was identical to the dCas9 counterpart.
Gibson assembly was used to clone the empty TALE-Sun
Tag backbone using plasmids pHRdSV40-dCas9-10XGCN4_
v4_P2A-BFP (Addgene, 60903) and pEF1a-TALE-DNMT3A-WT
(Addgene, 100937). Similarly, the dCas9-SunTag construct was as-
sembled from pGK-dCas9-DNMT3A-WT (V3; Addgene, 100938),
pHRdSV40-dCas9-10XGCN4_v4_P2A-BFP (Addgene, 60903), and
a poly(A) gBlock sequence (IDT). Following this, pHRdSV40-scFv-
GCN4-sfGFP-VP64-GB1-NLS (Addgene, 60904), pEF1a-TALE-
DNMT3A-WT (Addgene, 100937), and a gBlock linker sequence
(IDT) was used to assemble αGCN4-DNMT3A, which was also
used to create the DNMT3A FEER > AAAA mutation. This same
backbone was used to Gibson assemble the αGCN4-mCherry con-
trol plasmid, where the DNMT3A domain was replaced with a
mCherry fluorophore. Furthermore, restriction ligation was used
to insert TALE targeting sequences within the empty TALE-SunTag
backbone using MluI and AfeI (NEB). TALE DNA-binding domain
inserts were synthesized in-house using iterative capped assembly
as previously described (Briggs et al. 2012). Finally, gRNA plasmids
were synthesized according to the protocol by Mali et al. (2013),
and target sequences for TALEs and gRNA are listed in Supple-
mental Table S2. All plasmids constructed for this study can be
found at https://www.addgene.org/browse/article/28191639/.
Targeted BS-PCR primer design and sequencing
For each bisulfite PCR amplicon, primers were designed with
MethPrimer tool (Li and Dahiya 2002) (http://www.urogene.org/
cgi-bin/methprimer/methprimer.cgi) with all parameters set to de-
fault except the following: product size 200–400 bp; primer Tm
min: 55°C, opt: 60°C and max: 64°C; primer size min: 20 nt, opt:
25 nt and max: 30 nt. Each primer pair was tested in a 15 µL
PCR reaction with either NEB EpiMark (NEB, M0490L) or 2×
MyTaq (Bioline, BIO-25041) for a range of annealing temperatures
ranging from 50°C–64°C for 40 cycles. Primers that amplified spe-
cific products of the expected size were used, and these amplicons
were confirmed as our regions of interest via Sanger sequencing.
Five-hundred nanograms of extracted genomic DNA from trans-
fected HeLa or MCF-7 cells and 0.5% spiked in lambda DNA (non-
conversion control) was bisulfite converted using the EZ DNA-
methylation-gold kit (Zymo Research, catalog no. D5006) follow-
ing the manufacturer’s instructions. We used 20 ng of bisulfite
converted DNA for generating PCR products, which were subse-
quently pooled in an equimolar ratio and purified by Agencourt
AMPure XP beads (Beckman Coulter, catalog no. A63880).
Libraries were prepared by A-tailing and ligating Illumina-compat-
ible Y-shaped adapters to amplicons that were amplified by three
PCR cycles and subsequently purified by Agencourt AMPure XP
beads (Beckman Coulter, catalog no. A63880). Single-end 300-bp
sequencing was performed on an Illumina MiSeq platform.
qRT-PCR
Transfected HeLa and HEK293T cells were harvested with trypsin,
washed with Dulbecco’s phosphate-buffered saline (dPBS), and
centrifuged at 300g for 3 min, and then RNA was extracted using
RNeasyMini Kit (Qiagen, #74104). A cDNA library wasmade using
SuperScript IV Reverse Transcriptase (ThermoFisher, #18090050)
supplemented with poly d(T) and random hexamer reverse tran-
scription primer mix with 500 ng of RNA. qPCR primers (listed
in Supplemental Table S2) were designed using Primer 3 for
GAPDH, RPS18, and HSPC3 as housekeeping controls and
TMEM206 as the target. Luna qPCR universal master mix (Gene-
search, #M3003E) was used for qPCR, along with 2 µL of 1:5 dilut-
ed cDNA for each reaction. Activation was analyzed with the
Applied Biosystems ViiA7 instrument with the following program:
95°C for 3 min, followed by 40 cycles at 95°C for 10 sec, 63°C for
20 sec, and then 72°C for 5 sec. Gene expression levels were nor-
malized to the geometric mean of the three control genes with
ΔΔCt calculated by comparing to the untransfected samples.
ChIP-sequencing
Transfected HeLa cells were used for performing ChIPs for CTCF
and NRF1 as described previously (Wang et al. 2012; Domcke
et al. 2015) with somemodifications. Briefly, cells were crosslinked
for 10min in 1% formaldehyde and quenched in 125mMglycine.
Chromatin was sheared (Covaris, S220) for 5 min, 5% duty cycle,
200 cycles per burst, and 140 watts peak output and incubated
with either a CTCF (Cell Signaling, 2899B), NRF1 (Abcam,
ab55744), HA (Biolegend, 901502), or Ty1 (Sigma, SAB4800032)
antibody and subsequently conjugated to a 50:50 mix of protein
A/G Dynabeads (Invitrogen, M-280). After wash steps, DNA was
eluted, crosslinks were reversed, and immunoprecipitated DNA
was purified by Agencourt AMPure XP beads (Beckman Coulter,
catalog no. A63880). Libraries were prepared from the entire
ChIP eluate volume containing either 1 ng or 0.1 ng inputmaterial
per replicate for CTCF or NRF1, respectively, using the ThruPLEX
DNA-seq 12S kit (Rubicon Genomics, R400429). After limited
PCR amplification, libraries were purified using Agencourt
AMPure XP beads (Beckman Coulter, catalog no. A63880), and
eluted in a final volume of 20 µL. Single-end 100 bp sequencing
was performed on an Illumina HiSeq 1500.
ChIP-bs-seq
ChIP was performed using CTCF and NRF1 antibodies as stated
above. Either 1 ng or 10 ng per replicate of CTCF and NRF1 ChIP
eluate was used and subjected to bisulfite conversion using
Zymo methylation direct kit (Zymo Research, D5020). Bisulfite
converted DNA was immediately handled for library preparation
using the Accel-NGS Methyl-Seq DNA library kit (Swift
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Biosciences, catalog no. 30024) following the manufacturer’s in-
structions. Libraries were amplified for either nine or 13 cycles
for CTCF and NRF1, respectively. Single-end 100-bp sequencing
was performed on an Illumina HiSeq 1500.
Targeted enrichment for determining off-target DNA
methylation deposition
HeLa cells were transfected with pEF1a-GFP-Puro and pEF1a-
mCherry for control baseline or pGK-dCas9-Suntag-tagBFP2,
pEF1a-mCherry-SHB1 sgRNA, and pEF1a-αGCN4-DNMT3A for
targeted methylation at SHB locus in triplicate. Transfected cells
were sorted for GFP and mCherry positive (control baseline) or
GFP, mCherry and BFP positive (targeted methylation at SHB lo-
cus) and subjected to DNA extraction using the ISOLATE II DNA
extraction kit (Bioline, catalog no. BIO-52067). We used 250 ng
of genomic DNA from each replicate for library preparation and
subsequently pooled for target enrichment using the TruSeqmeth-
yl capture EPIC library prep kit (Illumina, catalog no. FC-151-
1002) following manufacturer’s instructions. Libraries were bisul-
fite converted using EZ DNA methylation Lightning kit (Zymo
Research, D5030) and amplified for 10 cycles. Single-end 100 bp
sequencing was performed on an Illumina HiSeq 1500.
Western blot
HeLa cells were seeded at 80% confluency and transfected with
equal amounts of sterilized plasmids dC9-D3A high (or dC9-
D3A) and SHB-1-sgRNA to 15.8 µg, along with three times the
amount of FuGENE HD transfection reagent (Promega, catalog
no. E2311) following the manufacturer’s instructions. Samples
were either collected 48 h post-transfection or following an addi-
tional 48 h after puromycin selection (2 µg/mL, Life Technologies,
catalog no. A1113803) to replicate the conditions employed while
generating cells used forDNAmethylation analysis. Cells were har-
vested and spun down at 300g for 5 min and then lysed in RIPA
buffer with 4% SDS and 1 µL Benzonase (Sigma, catalog no.
E1014). Samples were further lysed by sonication (Covaris, S220)
and gently pipetted with a 21G needle (Livingston, catalog no.
DN21Gx1.0LV) to reduce viscosity. Standard immunoblotting
was performed on 50 µg of cell lysate for each sample. Mouse
anti-Ty1 (1:1000, Sigma, catalog no. AB4800032) antibody was
used, alongwithmouse anti-α-Tubulin (1:1000, GenScript, catalog
no. A01410-40) as the loading control.
Data processing
ChIP-seq and ChIP-bs-seq data were quality checked and hard
trimmed (Accel-NGS Methyl-Seq DNA library kit requirements)
using Trimmomatic (Bolger et al. 2014) with the following
parameters: ILLUMINACLIP:2:30:10, LEADING:3, TRAILING:3,
SLIDINGWINDOW:4:20, MINLEN:25. Trimmed ChIP-seq data
were mapped to the human genome (GRCh37/hg19) using
Bowtie1.1.1 (Langmead et al. 2009) with the options “- -wrapper
basic-0 -m 1 -S -p 4 -n 1” allowing up to onemismatch. Readsmap-
ping to multiple locations were then excluded, and reads with
identical 5′ ends and strand were presumed to be PCR duplicates
and were excluded using Picard MarkDuplicates. Bigwig coverage
tracks and differential peak calling were produced by THOR
(Allhoff et al. 2016) using TMM normalization. Normalized peak
counts were analyzed by edgeR (Robinson et al. 2010) for fold-
change and filtered by multiple-test-corrected false-discovery rate
(FDR < 0.05). Targeted bs-PCR-seq data and ChIP-bs-seq data
were mapped to the GRCh37/hg19 genome and processed using
BS-Seeker2 (Guo et al. 2013) with default parameters, Bowtie 1,
and allowing for one mismatch. Data processing pipelines lever-
aged sambamba (Tarasov et al. 2015) and Gnu parallel (Tange
2011) to speed up sample analysis. Thiswork used regions and sites
that are well established in hg19 and did not improve in human
genome assembly hg38. Further, previous work that described spe-
cific CTCF binding sites (Maurano et al. 2015), as well as NRF1
binding sites (Domcke et al. 2015), that were reported to be DNA
methylation sensitive were also aligned to hg19. Consequently,
conclusions drawn from our manuscript would not change based
on aligning to hg38.
Data access
All HeLa-S3 raw and processed data generated in this study (WGBS-
seq, ChIP-seq, ChIP-bs-seq, bsPCR-seq, and TSC-bs-seq) have been
submitted to the NCBI Gene Expression Omnibus (GEO; http://
www.ncbi.nlm.nih.gov/geo/) under accession number GSE107607.
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